ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Roferon A Application Marred By Mission Data, Protocol, Compliance

September 24, 1999

NCAB Committee Urged to Seek Surgical Oncology Certification

June 14, 1985

Second Irregularity In NSABP Data Found; Fisher Takes Leave As Group’s Chairman

April 1, 1994

Armand Hammer Panel chairman; DeVita Announces Greenwald Appointment; Adamson To Be DCCP Director

October 9, 1981

Trial Tests Selenium, Vitamin E In Prostate Cancer Prevention.

July 27, 2001

NIH Responds To IOM Report On Women’s Health Initiative

November 12, 1993